305 related articles for article (PubMed ID: 27362330)
1. Potential new complication in drug therapy development for amyotrophic lateral sclerosis.
Garbuzova-Davis S; Thomson A; Kurien C; Shytle RD; Sanberg PR
Expert Rev Neurother; 2016 Dec; 16(12):1397-1405. PubMed ID: 27362330
[TBL] [Abstract][Full Text] [Related]
2. Cord blood as a potential therapeutic for amyotrophic lateral sclerosis.
Garbuzova-Davis S; Ehrhart J; Sanberg PR
Expert Opin Biol Ther; 2017 Jul; 17(7):837-851. PubMed ID: 28443372
[TBL] [Abstract][Full Text] [Related]
3. Blood-CNS Barrier Impairment in ALS patients versus an animal model.
Garbuzova-Davis S; Sanberg PR
Front Cell Neurosci; 2014; 8():21. PubMed ID: 24550780
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis.
Sasaki S
Neuropathology; 2015 Dec; 35(6):518-28. PubMed ID: 26242689
[TBL] [Abstract][Full Text] [Related]
5. GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease.
Li K; Hala TJ; Seetharam S; Poulsen DJ; Wright MC; Lepore AC
Neurobiol Dis; 2015 Jun; 78():12-23. PubMed ID: 25818008
[TBL] [Abstract][Full Text] [Related]
6. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences.
Kato S
Acta Neuropathol; 2008 Jan; 115(1):97-114. PubMed ID: 18026741
[TBL] [Abstract][Full Text] [Related]
7. High-throughput drug screens for amyotrophic lateral sclerosis drug discovery.
McGown A; Stopford MJ
Expert Opin Drug Discov; 2018 Nov; 13(11):1015-1025. PubMed ID: 30317895
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic targets for amyotrophic lateral sclerosis.
Kuzma-Kozakiewicz M; Kwiecinski H
Expert Opin Ther Targets; 2011 Feb; 15(2):127-43. PubMed ID: 21133819
[TBL] [Abstract][Full Text] [Related]
9. Management and therapeutic perspectives in amyotrophic lateral sclerosis.
Mathis S; Couratier P; Julian A; Vallat JM; Corcia P; Le Masson G
Expert Rev Neurother; 2017 Mar; 17(3):263-276. PubMed ID: 27644548
[TBL] [Abstract][Full Text] [Related]
10. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders.
Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V
J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087
[TBL] [Abstract][Full Text] [Related]
11. Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS).
Van Dyke JM; Smit-Oistad IM; Macrander C; Krakora D; Meyer MG; Suzuki M
Exp Neurol; 2016 Mar; 277():275-282. PubMed ID: 26775178
[TBL] [Abstract][Full Text] [Related]
12. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis.
Miyazaki K; Ohta Y; Nagai M; Morimoto N; Kurata T; Takehisa Y; Ikeda Y; Matsuura T; Abe K
J Neurosci Res; 2011 May; 89(5):718-28. PubMed ID: 21337372
[TBL] [Abstract][Full Text] [Related]
13. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.
Kumar V; Islam A; Hassan MI; Ahmad F
Eur J Med Chem; 2016 Oct; 121():903-917. PubMed ID: 27372371
[TBL] [Abstract][Full Text] [Related]
15. Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis.
Ng SK; Higashimori H; Tolman M; Yang Y
Exp Neurol; 2015 May; 267():115-22. PubMed ID: 25779930
[TBL] [Abstract][Full Text] [Related]
16. Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery.
Van Damme P; Robberecht W
Expert Opin Investig Drugs; 2014 Jul; 23(7):955-63. PubMed ID: 24816247
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
18. MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.
Glajch KE; Ferraiuolo L; Mueller KA; Stopford MJ; Prabhkar V; Gravanis A; Shaw PJ; Sadri-Vakili G
PLoS One; 2016; 11(10):e0164103. PubMed ID: 27716798
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneally administered IgG from patients with amyotrophic lateral sclerosis or from an immune-mediated goat model increase the levels of TNF-α, IL-6, and IL-10 in the spinal cord and serum of mice.
Obál I; Klausz G; Mándi Y; Deli M; Siklós L; Engelhardt JI
J Neuroinflammation; 2016 May; 13(1):121. PubMed ID: 27220674
[TBL] [Abstract][Full Text] [Related]
20. Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration.
Lewandowski SA; Nilsson I; Fredriksson L; Lönnerberg P; Muhl L; Zeitelhofer M; Adzemovic MZ; Nichterwitz S; Lawrence DA; Hedlund E; Eriksson U
Acta Neuropathol; 2016 Mar; 131(3):453-64. PubMed ID: 26687981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
